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Abstract
Background: Hyaluronan, an unsulfated glycosaminoglycan, while being closely linked to
osteoclast function several years ago, has received little attention lately. Given recent new
knowledge of hyaluronan's possible cell binding abilities, it is important to re-examine the role of
this polysaccharide in bone homeostasis.
Discussion: Previously published data demonstrating a linkage between induction of hyaluronan
synthesis and osteoclast-mediated bone resorption are reviewed. Suggestions are made involving
the cell binding ability of hyaluronan and its potential to mediate osteoclast binding to bone surfaces
and its potential to serve as a diffusion barrier and participate in the sealing zone required for
osteoclast-mediated bone resorption.
Summary: This brief article summarizes previous studies linking HA to bone resorption and
suggests roles for hyaluronan in the process of bone resorption.
Background
Hyaluronan (HA) is an unsulfated glycosaminoglycan
consisting of a single repeating disaccharide unit (1,4-glu-
curonic acid-β-1,3-N-acetylglucosamine-β). HA is about
1–10% of cartilage glycosaminoglycans, but it is also
widely distributed in other tissues, e.g. in the skin, the eye,
and in most body liquids [1]. HA is an important compo-
nent of connective tissue matrices where its functions
include promoting matrix assembly and tissue hydration
and viscosity of some fluids, and modulating cell-cell or
cell-matrix interactions [1]. Recently, additional roles for
HA in cell signaling have been elucidated which involve
cellular hyaladherins such as CD44 and RHAMM
(CD168) that have specific downstream signaling path-
way(s) which can mediate HA-dependent functions [2].
Linkage of hyaluronan synthesis to bone resorption
Several studies [3-5] demonstrated that treatment in vivo
with parathyroid gland extract (PTE) resulted in increased
bone synthesis of hexosamine-containing compound(s).
Based on such findings, Severson et al. [6] used organ cul-
tures of neonatal mouse calvaria, treated with PTE and
then labeled with 3H-glucosamine (glcN), to demonstrate
that PTE caused a 4-fold increase in papain-resistant mac-
romolecular material that was identified as hyaluronic
acid, now called hyaluronan (HA). Luben and coworkers
provided data that clearly linked parathyroid hormone
(PTH)-induced synthesis of HA to bone resorption. Using
organ cultures of bones pre-labeled in vivo with 45Ca++,
they demonstrated that in vitro treatment with PTH fol-
lowed by radiolabeling with 3H-glcN resulted in a 3–4-
fold increase in HA synthesis [7]. This increase was detect-
able by 4 h and was maximal at 24 h. Changes in 45Ca++
release followed a parallel course but with a delayed onset
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glucosamine to the culture medium in the absence or
presence of PTH had no significant effect on 45Ca++
release. Using a similar system to assay calcium release
and HA synthesis, Luben and Cohn [8] also found that
addition of calcitonin to PTH-stimulated cultures caused
HA synthesis and, subsequently, calcium release to return
to control levels. After 24 h in the presence of both hor-
mones, an "escape" phenomenon [9] was observed, i.e.,
the rate of HA synthesis and calcium release again
increased, with the former preceding the latter. These data
strongly linked induction of HA synthesis to osteoclastic
resorption, prompting the authors to suggest "that a
change in hyaluronate synthesis is a metabolic prerequi-
site for demineralization". Luben et al., [7] speculated that
the role for HA in bone resorption could be to act as a cal-
cium binding agent, to act as a barrier to the diffusion of
enzymes away from the resorption site or to regulate the
mobility of osteoclasts or osteoclast precursor cells. To our
knowledge, none of these possibilities has been proven
nor excluded and all deserve additional exploration.
Thus, though HA's role was not known, sufficient evi-
dence existed linking HA to bone resorption that Wong
and coworkers [10,11] utilized PTH stimulation of HA
synthesis as a specific marker during the purification of
osteoclastic cells. The studies cited above and others
prompted Stern and Raisz [12] to comment in a discus-
sion of markers of bone resorption that "hyaluronic acid
seems to be the most appropriate for study because,
unlike the other biochemical changes, it has been clearly
linked to bone resorption."
Discussion
Role of HA in cell binding
The requirement for osteoclasts to bind to bone surfaces
prior to assuming their resorptive role is well docu-
mented, though the means by which they do so is not.
Recent work has suggested that osteoclasts utilize
integrins, in particular the vitronectin receptor, ανβ3, to
bind to one or more of the cell adhesion proteins, e.g.
osteopontin or bone siaoloprotein [13,14], though such
binding may not occur at the sealing zone as previously
supposed [15]. Since osteoclasts have recently been
shown to possess cell surface proteins capable of binding
to HA [16], in particular CD44, a cell surface HA binding
protein [17] capable of supporting cell adhesion [18], HA
may also regulate the osteoclast's ability to bind to bone
surfaces by acting alone or in conjunction with osteopon-
tin, bone siaoloprotein or other matrix proteins (likely
synthesized by osteoclasts). Recent work by Spessoto et
al., [19] supports this scenario and work by Suzuki et al.,
[20] confirms that osteoclasts from CD44-/- mice are
defective in bone resorption.
In addition, given the large hydrodynamic volume of HA,
it seems possible that it could participate in forming a dif-
fusion barrier underneath the osteoclast, presumably at
the sealing zone. One could speculate that any HA present
in the ruffled membrane area would be degraded by lyso-
somal enzymes secreted from the osteoclasts.
It is instructive to note that while little is known about the
bone enzymes responsible for degrading HA, i.e., hyaluro-
nidase (EC 3.2.1.35), β-D-glucuronidase (EC 3.2.1.31),
and N-acetyl-β-D-hexosaminidase (EC 3.2.1.30), genetic
deficiencies of β-D-glucuronidase (Sly syndrome, [21]) or
N-acetyl-β-D-hexosaminidase (Sandhoff Disease, [22]),
result in numerous skeletal deformities, suggesting that
these enzymes have important roles in normal bone
homeostasis.
On the other hand, an additional role of HA may be in
modulating osteoblast adhesion to osteoid or bone sur-
faces. In their model of hormonal regulation of bone
resorption, Rodan and Martin [23] suggested that PTH
induces osteoblasts, which form a contiguous layer on the
bone surface, to change shape, thereby allowing osteo-
clasts access to the bone surface, a prerequisite for bone
resorption. Given that osteoblasts exhibit vectorial secre-
tion, i.e., directed toward the underlying bone surface,
and that HA has a large molecular size and hydrodynamic
volume, HA synthesized by osteoblasts may prove to be a
molecular lever of sorts, capable of prying osteoblasts
from the osteoid surface or from one another, disrupting
the continuity of the lining layer of cells. Thereafter, in
such a scenario, the HA could serve as an adhesion sub-
strate for incoming osteoclasts and, possibly, act as a dif-
fusion barrier at the sealing zone. In this regard the recent
findings of Midura et al., are pertinent – they found that
HA content of bone extracellular matrix was substantially
enhanced by PTH treatment and that this was a direct
response to the peptide hormone [24].
Another scenario is suggested by the recent work by Fujii
et al., [25] who demonstrated that ligation of osteoblast
CD44 with HA regulates adhesion molecule expression of
osteoblasts and increases their binding to macrophage-
like cells. These authors suggested that the interactions of
CD44 and HA may play a role in osteoclastogenesis.
Summary
1. HA synthesis is tightly coupled to onset of bone resorp-
tion
2. HA's roles in cell adhesion and in limiting diffusion
suggest mechanisms for its involvement in osteoclast-
mediated bone resorptionPage 2 of 3
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2004, 5 http://www.biomedcentral.com/1471-2474/5/12Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
3. These mechanisms include cell binding, and/or acting
as a molecular lever or diffusion barrier
4. Additional studies are needed to clarify the roles that
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